We are a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. We are currently developing three product candidates under our INOpulse platform, a proprietary pulsatile nitric oxide drug delivery system. The first is for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The second product candidate is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third is for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc). All three of our programs are in Phase 2 development.
The INOpulse platform is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. Use of inhaled nitric oxide is approved by the U.S. Food and Drug Administration (FDA) and other regulatory authorities across the world to treat persistent pulmonary hypertension of the newborn. The INOpulse technology utilizes targeted pulsatile delivery of inhaled nitric oxide, allowing it to be extended into chronic use applications. Bellerophon has exclusive worldwide rights to the ongoing INOpulse programs and related intellectual property.